Labetalol HCl|AH-5158 hydrochloride; Sch-15719W; NSC 290312; AH 5158A; Labetalol (hydrochloride); Labetalol hydrochloride|柳胺苄心定|Adrenergic Receptor|for research only|Ambeed

首页 / 抑制剂/激动剂 / / 肾上腺素能受体 / Labetalol HCl/盐酸拉贝洛尔

Labetalol HCl/盐酸拉贝洛尔 {[allProObj[0].p_purity_real_show]}

货号：A155972 同义名： 柳胺苄心定 / AH-5158 hydrochloride; Sch-15719W

Laβlol HCl is a third generation selective α-1-adrenergic antagonist and non-selective β-adrenergic antagonist, used to treat high blood pressure.

Labetalol HCl/盐酸拉贝洛尔化学结构
CAS号：32780-64-6

Labetalol HCl/盐酸拉贝洛尔 3D分子结构
CAS号：32780-64-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Labetalol HCl/盐酸拉贝洛尔纯度/质量文件产品仅供科研

货号：A155972 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

肾上腺素能受体亚型比较

产品名称	Adrenergic Receptor ↓ ↑	α-adrenergic receptor ↓ ↑	β-adrenergic receptor ↓ ↑	纯度
Ivabradine HCl	✔			98%
Maprotiline HCl	✔			98%
Cisatracurium besylate	✔			96%
Yohimbine HCI		✔		99+%
BMY 7378		++ α2C-adrenoceptor, pKi: 6.54 α1D-adrenoceptor, pKi: 5.1	+ β1-adrenoceptor, pIC50: 5.1	97%
Asenapine maleate		++++ α2B-adrenergic receptor, pKi: 8.9 α2A-adrenergic receptor, pKi: 8.9		97%
Piribedil		++ adrenoceptor α2A, pKi: 7.1 adrenoceptor α2C, pKi: 7.2		98%
Prazosin HCl		✔		95%
Silodosin		✔		98%
Phenoxybenzamine HCl		✔		98%
Labetalol HCl		✔		98+%
Naftopidil		+++ α1D-adrenergic receptor, Ki: 20 nM α1A-adrenergic receptor, Ki: 3.7 nM		98%
Naftopidil 2HCl		+ α1-adrenergic receptor, IC50: 0.2 μM		99%
Alfuzosin HCl		✔		98%
Terazosin HCl		✔		99%
Atipamezole		✔		95%
Phentolamine methanesulfonate salt		✔		99%
Carvedilol		✔		99%
Doxazosin mesylate		✔		99%
Tolazoline HCl		✔		98%
Esmolol HCl			✔	95%
Propranolol HCl			++ β-adrenergic receptor, IC50: 12 nM	99%
Zenidolol HCl			++++ β1-adrenergic receptor, Ki: 611nM β2-adrenergic receptor, Ki: 0.7nM	98%
Acebutolol HCl			✔	97+%
Carteolol HCl			✔	98+%
Betaxolol			✔	99%
Betaxolol HCl			+ β1-adrenergic receptor, IC50: 6 μM	97%
Bisoprolol			✔	97%
Sotalol HCl			✔	95+%
Nebivolol HCl			+++ β1-adrenoceptor, IC50: 0.8 nM	99%
Metoprolol			✔	98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Labetalol HCl/盐酸拉贝洛尔生物活性

靶点	α-adrenergic receptor
描述	Labetalol hydrochloride is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure.

Labetalol HCl/盐酸拉贝洛尔临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01316952	-		Completed	-	-
NCT02135315	Acute Coronary Syndrome	Not Applicable	Recruiting	December 2017	Tunisia ... 展开 >> university of Monastir Recruiting Monastir, Tunisia, 5000 Contact: Nouirahead of departement 216073532014 semir.nouira@rns.tn Contact: Fattouma Bourguiba University Hospital +216 73 106 085 semir.nouira@rns.tn Principal Investigator: semir nouira, professor 收起 <<
NCT01688648	Unstable Angina ... 展开 >> Coronary Artery Bypass Graft Dexmedetomidine Lidocaine Myocardial Injury Arrhythmia Blood Electrolyte Balance 收起 <<	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<

Labetalol HCl/盐酸拉贝洛尔参考文献

[1]Garse H, Vij M, et al. Formulation and evaluation of a gastroretentive dosage form of labetalol hydrochloride. Arch Pharm Res. 2010 Mar;33(3):405-10.

[2]Hopkins R, Martin LE, Bland R. The metabolism of labetalol in animals and man. Biochem Soc Trans. 1976;4(4):726-9.

Labetalol HCl/盐酸拉贝洛尔实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.70mL

2.74mL

1.37mL

27.41mL

5.48mL

2.74mL

Labetalol HCl/盐酸拉贝洛尔技术信息

CAS号	32780-64-6
分子式	C₁₉H₂₅ClN₂O₃
分子量	364.87
SMILES Code	O=C(N)C1=CC(C(O)CNC(CCC2=CC=CC=C2)C)=CC=C1O.[H]Cl
MDL No.	MFCD00057663

别名	柳胺苄心定 ;AH-5158 hydrochloride; Sch-15719W; NSC 290312; AH 5158A; Labetalol (hydrochloride); Labetalol hydrochloride
运输	蓝冰
InChI Key	WQVZLXWQESQGIF-UHFFFAOYSA-N
Pubchem ID	71412

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, room temperature

溶解方案

细胞实验：

DMSO: 105 mg/mL(287.78 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 20 mg/mL(54.81 mM)，配合低频超声助溶

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01316952	-		Completed	-	-
NCT02135315	Acute Coronary Syndrome	Not Applicable	Recruiting	December 2017	Tunisia ... 展开 >> university of Monastir Recruiting Monastir, Tunisia, 5000 Contact: Nouirahead of departement 216073532014 semir.nouira@rns.tn Contact: Fattouma Bourguiba University Hospital +216 73 106 085 semir.nouira@rns.tn Principal Investigator: semir nouira, professor 收起 <<
NCT01688648	Unstable Angina ... 展开 >> Coronary Artery Bypass Graft Dexmedetomidine Lidocaine Myocardial Injury Arrhythmia Blood Electrolyte Balance 收起 <<	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT01942356	Acute Cholecystitis ... 展开 >> Chronic Cholecystitis 收起 <<	Not Applicable	Completed	-	United States, Texas ... 展开 >> University Hospital San Antonio, Texas, United States, 78229 收起 <<
NCT00848991	Cranitomy Surgery	Phase 3	Completed	-	United States, New Jersey ... 展开 >> Cooper University Hospital Camden, New Jersey, United States, 08103 收起 <<
NCT00226096	CVA (Cerebrovascular Accident)... 展开 >> Cerebral Hemorrhage Intracranial Hemorrhages 收起 <<	Not Applicable	Completed	-	Australia, New South Wales ... 展开 >> Concord Hospital Concord, New South Wales, Australia, 2138 Gosford Hospital Gosford, New South Wales, Australia, 2250 St George Hospital Kogarah, New South Wales, Australia, 2217 John Hunter Hospital Newcastle, New South Wales, Australia, 2310 St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Royal Prince Alfred Hospital Sydney, New South Wales, Australia, 2050 Westmead Hospital Westmead, New South Wales, Australia, 2145 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 Australia, Victoria Royal Melbourne Hospital Melbourne, Victoria, Australia, 3050 St Vincent's Hospital Melbourne, Victoria, Australia, 3065 Box Hill Hospital Melbourne, Victoria, Australia, 3128 Alfred Hospital Melbourne, Victoria, Australia, 3181 Austin Health Melbourne, Victoria, Australia Monash Medical Centre Melbourne, Victoria, Australia Australia, Western Australia Sir Charles Gairdner Hospital Perth, Western Australia, Australia, 6009 China Regional Coordinating Centre: Peking University First Hospital Beijing, China, 100034 Hospitals in China, c/o The George Institute China Beijing, China Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University Shanghai, China, 200025 New Zealand North Shore Hospital Auckland, New Zealand Christchurch Hospital Christchurch, New Zealand 收起 <<
NCT02258100	-		Completed	-	United States, Illinois ... 展开 >> Evanston Hospital Evanston, Illinois, United States, 60201 收起 <<
NCT00716079	Intracerebral Hemorrhage ... 展开 >> Stroke Hypertension 收起 <<	Not Applicable	Completed	-	-
NCT00716079	-		Completed	-	-
NCT00952081	Hypertension ... 展开 >>Brain Tumor Epilepsy 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> NYU Langone Medical Center, Department of Anesthesiology New York, New York, United States, 10016 收起 <<
NCT03511118	-		Recruiting	September 22, 2019	United States, North Carolina ... 展开 >> Duke University Maternal and Fetal Medicine Recruiting Durham, North Carolina, United States, 27705 Contact: Kristin Weaver 919-613-9630 obresearch@duke.edu Principal Investigator: Brenna Hughes, MD United States, Washington University of Washington Recruiting Seattle, Washington, United States, 98195-7630 Contact: Maggie Leahy 540-525-0121 maleahy@u.washington.edu Principal Investigator: Mary Hébert, Pharm.D 收起 <<
NCT00952081	-		Completed	-	-
NCT01422616	Ischemic Stroke ... 展开 >> High Blood Pressure 收起 <<	Phase 3	Recruiting	February 2019	Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Recruiting Sydney, New South Wales, Australia, 2050 Contact: Craig S Anderson, MD +61 2 933 4500 canderson@georgeinstitute.org.au 收起 <<
NCT00684489	Hypertension	Not Applicable	Completed	-	-
NCT01526876	Hypertension	Phase 4	Withdrawn(Terminated by Sponso... 展开 >>r) 收起 <<	-	-
NCT01176565	Intracerebral Hemorrhage	Phase 3	Terminated(Planned interim ana... 展开 >>lysis no significant outcome differences between groups) 收起 <<	-	-
NCT01068002	-		Unknown	June 2010	Israel ... 展开 >> Ha'Emek Medical Center Recruiting Afula, Israel, 18101 Contact: Limor I Bushari, MD 972502000741 limor_il@clalit.org.il Contact: Nachum Zohar 972547696562 nachun_zo@clalit.org.il Principal Investigator: Limor I Bushari, MD Sub-Investigator: Raed Salim, MD Sub-Investigator: Nachum Zohar, MD 收起 <<
NCT02327793	Stroke, Acute	Phase 2	Completed	-	Canada, Alberta ... 展开 >> University of Alberta Edmonton, Alberta, Canada, T6G 2B7 收起 <<
NCT00194974	Pregnancy Toxemia ... 展开 >> Hypertension Proteinuria 收起 <<	Phase 1 Phase 2	Withdrawn(Lack of funding)	-	United States, New York ... 展开 >> The New York PresbyterianHospital-Weill Medical College of Cornell University New York, New York, United States, 10021 收起 <<
NCT02281838	Intracerebral Hemorrhage	Phase 2	Recruiting	-	Canada, Alberta ... 展开 >> University of Alberta Recruiting Edmonton, Alberta, Canada, T6G 2B7 Contact: Ken S Butcher, MD, PhD 7804072171 ken.butcher@ualberta.ca Principal Investigator: Ken S Butcher, MD, PhD Canada, Ontario Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1Y 4E9 Contact: Dar Dowlatshahi 613-761-4709 ddowlat@toh.on.ca Principal Investigator: Dar Dowlatshahi, MD 收起 <<
NCT01248169	-		Completed	-	United States, Mississippi ... 展开 >> Wiser Hospital for Women and Infants at the University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 收起 <<
NCT03245970	Chronic Hypertension Complicat... 展开 >>ing Pregnancy (Diagnosis) Preeclampsia 收起 <<	Early Phase 1	Recruiting	April 24, 2019	United States, Tennessee ... 展开 >> HIgh Risk Obstetrical Consultants Recruiting Knoxville, Tennessee, United States, 37920 Contact: Craig V. Towers, MD 865-305-8888 ctowers@utmck.edu Contact: Beth W Weitz, APN 865-305-8888 bweitz@utmck.edu Sub-Investigator: Bobby Howard, MD 收起 <<
NCT02299414	Hypertension	Phase 4	Recruiting	December 2021	-
NCT01176565	-		Terminated(Planned interim ana... 展开 >>lysis no significant outcome differences between groups) 收起 <<	-	-
NCT00963976	Intracerebral Hemorrhage	Phase 2	Completed	-	Canada, Alberta ... 展开 >> University of Calgary Calgary, Alberta, Canada University of Alberta Edmonton, Alberta, Canada, T6G2B7 Grey Nuns Hospital Edmonton, Alberta, Canada, T6L 5X8 Canada, Ontario University of Ottawa Ottawa, Ontario, Canada 收起 <<
NCT03105661	Obesity, Morbid ... 展开 >> Preeclampsia 收起 <<	Early Phase 1	Recruiting	March 4, 2020	United States, Tennessee ... 展开 >> University of Tennessee Medical Center Recruiting Knoxville, Tennessee, United States, 37920 Contact: Craig V. Towers, MD 865-305-8888 ctowers@utmck.edu Contact: Beth Weitz, APN 865-305-8888 bweitz@utmck.edu 收起 <<
NCT02933593	Hypertension	Not Applicable	Withdrawn(PI withdrew the prot... 展开 >>ocol) 收起 <<	-	-
NCT00394537	Bronchoscopy	Phase 4	Completed	-	Israel ... 展开 >> Rabin Medical Center Petach Tikva, Israel, 49100 收起 <<
NCT02531490	Hypertension, Pregnancy-Induce... 展开 >>d Pre-Eclampsia 收起 <<	Phase 4	Recruiting	April 2020	Netherlands ... 展开 >> Maastricht UMC Recruiting Maastricht, Netherlands Contact: Eva Mulder eva.mulder@mumc.nl 收起 <<
NCT03059316	Controlled Hypotension for Nas... 展开 >>al Surgeries 收起 <<	Early Phase 1	Completed	-	-
NCT03506724	Hypertension in Pregnancy ... 展开 >> Preeclampsia 收起 <<	Phase 4	Recruiting	January 2019	United States, New York ... 展开 >> Maimonides Hospital Recruiting Brooklyn, New York, United States, 11219 Contact: Poroshat Shekarloo, MD pshekarloo@maimonidesmed.org Mount Sinai West Recruiting New York, New York, United States, 10019 Contact: Dyese Taylor, MD 212-523-7579 dyese.taylor@mountsinai.org Principal Investigator: Dyese Taylor, MD 收起 <<
NCT02912910	-		Withdrawn(PI withdrew protocol... 展开 >>) 收起 <<	-	-
NCT01912677	Hypertension in Pregnancy ... 展开 >> Preeclampsia 收起 <<	Phase 4	Completed	-	India ... 展开 >> Daga Women's Hospital Nagpur, Maharashtra, India, 440003 Government Medical College Nagpur, Maharashtra, India, 440003 收起 <<
NCT00000297	Tobacco Use Disorder	Phase 2	Completed	-	United States, Minnesota ... 展开 >> University of Minnesota Minneapolis, Minnesota, United States, 55455 收起 <<
NCT01408524	Hypertension ... 展开 >>Craniotomy 收起 <<	Phase 1 Phase 2	Completed	-	-
NCT02997800	Bloodpressure ... 展开 >> Heart Rate 收起 <<	Phase 2	Recruiting	August 2019	Canada, Ontario ... 展开 >> Queen's University, Department of Anesthesiology Recruiting Kingston, Ontario, Canada, K7L 2V7 Contact: Debbie DuMerton Shore, RN (613)549-6666 ext 3224 shored@kgh.kari.net Contact: Robert Tanzola, MD, FRCPC (613)548-7827 tanzolar@kgh.kari.net 收起 <<
NCT03449277	Postpartum Preeclampsia	Phase 4	Recruiting	March 1, 2019	Egypt ... 展开 >> Hossam Ahmed Abd Ellah Recruiting Assiut, Egypt Contact: Hossam Ahmed Abd Ellah, MBBCH 0201119939775 drhaaada@gmail.com 收起 <<
NCT00000291	Cocaine-Related Disorders	Phase 2	Completed	-	United States, Minnesota ... 展开 >> University of Minnesota Minneapolis, Minnesota, United States, 55455 收起 <<
NCT00293735	Preeclampsia ... 展开 >>Pregnancy Induced Hypertension Gestational Hypertension Chronic Hypertension Superimposed Preeclampsia 收起 <<	Phase 2 Phase 3	Withdrawn(Lack of funding)	-	United States, Texas ... 展开 >> Baylor College of Medicine Houston, Texas, United States, 77030 India Institute of Maternal and Child Health Medicine Kerala, India, 673008 收起 <<
NCT01041066	Patients Who Are Intubated for... 展开 >> General Anesthesia Endotracheal Intubation 收起 <<	Not Applicable	Unknown	-	Korea, Republic of ... 展开 >> Seoul National University Bundang Hospital Recruiting Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707 Contact: Jung-Hee Ryu, Ph.D 82-31-787-7497 jinaryu@lycos.co.kr 收起 <<
NCT02426177	Postnatal Hypertension	Phase 3	Unknown	December 2016	-
NCT01114971	Laparoscopic Surgery	Phase 4	Completed	-	United States, California ... 展开 >> Cedars Sinai Medical Center Los Angeles, California, United States, 90048 收起 <<
NCT00765648	-		Completed	-	-
NCT03761888	-		Recruiting	May 2019	France ... 展开 >> Hôpital Béclère Recruiting Clamart, France, 92140 Contact: Mickaël SOUED +33145374273 mickael.soued@aphp.fr 收起 <<
NCT01538875	Hypertension, Pregnancy Induce... 展开 >>d 收起 <<	Phase 3	Completed	-	Panama ... 展开 >> Saint Thomas Maternity Hospital Panama, Panama 收起 <<
NCT00765648	Hypertensive Urgency	Phase 4	Completed	-	United States, Ohio ... 展开 >> Cleveland Clinic Cleveland, Ohio, United States, 44122 United States, Texas University of Texas Health Science Center Houston, Texas, United States 收起 <<
NCT02168309	-		Completed	-	-
NCT02050529	Hypertension, Pregnancy Induce... 展开 >>d Hydralazine Adverse Reaction Pre-eclampsia Pre-eclampsia Superimposed Pre-existing Hypertension 收起 <<	Phase 2	Completed	-	Pakistan ... 展开 >> Civil Hospital Karachi Karachi, Sindh, Pakistan, 74200 收起 <<
NCT03661346	Chronic Sinusitis	Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas Medical Branch Galveston, Texas, United States, 77550 收起 <<
NCT03325348	Severe Pre-Eclampsia, Antepart... 展开 >>um 收起 <<	Phase 2 Phase 3	Recruiting	January 15, 2018	Pakistan ... 展开 >> Services Institute of Medical Sciences Recruiting Lahore, Punjab, Pakistan Contact: TAYYIBA WASIM, FCPS +923008400197 tayyibawasim@yahoo.com Contact: Natasha Usman, FCPS natashausman5@hotmail.com 收起 <<
NCT02168309	Severe Postpartum Hypertension	Not Applicable	Completed	-	United States, California ... 展开 >> Cedars Sinai Medical Center Los Angeles, California, United States, 90048 收起 <<

Labetalol HCl/盐酸拉贝洛尔 {[allProObj[0].p_purity_real_show]}

Labetalol HCl/盐酸拉贝洛尔纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Labetalol HCl/盐酸拉贝洛尔质控信息

Labetalol HCl/盐酸拉贝洛尔生物活性

Labetalol HCl/盐酸拉贝洛尔临床研究

Labetalol HCl/盐酸拉贝洛尔参考文献

Labetalol HCl/盐酸拉贝洛尔实验方案

Labetalol HCl/盐酸拉贝洛尔技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Labetalol HCl/盐酸拉贝洛尔 {[allProObj[0].p_purity_real_show]}

Labetalol HCl/盐酸拉贝洛尔 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Labetalol HCl/盐酸拉贝洛尔 质控信息

Labetalol HCl/盐酸拉贝洛尔 生物活性

Labetalol HCl/盐酸拉贝洛尔 临床研究

Labetalol HCl/盐酸拉贝洛尔 参考文献

Labetalol HCl/盐酸拉贝洛尔 实验方案

Labetalol HCl/盐酸拉贝洛尔 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Labetalol HCl/盐酸拉贝洛尔纯度/质量文件产品仅供科研

Labetalol HCl/盐酸拉贝洛尔质控信息

Labetalol HCl/盐酸拉贝洛尔生物活性

Labetalol HCl/盐酸拉贝洛尔临床研究

Labetalol HCl/盐酸拉贝洛尔参考文献

Labetalol HCl/盐酸拉贝洛尔实验方案

Labetalol HCl/盐酸拉贝洛尔技术信息